By Hamayle Saeed, MD
October 31, 2026
The modern landscape of metabolic medicine is defined by a paradoxical disconnect. As a South Asian physician, I am acutely aware of the clinical guidelines that govern my own demographic. According to the American Diabetes Association (ADA), my body mass index (BMI) should be monitored with heightened vigilance; because Asian Americans are predisposed to developing metabolic disease at lower body weights, screening for diabetes should begin the moment our BMI exceeds 23.
My clinicians follow this guidance religiously. Yet, when I recently inquired about the potential of a GLP-1 receptor agonist—a class of drugs that has revolutionized the treatment of obesity—the response was a definitive "no."
The reasoning is rooted in a rigid, one-size-fits-all administrative framework. FDA-approved access to these medications typically hinges on a BMI threshold of 30, or 27 if the patient presents with a weight-related comorbidity. At a BMI of 26.5, I fall into a dangerous "blind spot": I am considered too thin to qualify for preventative treatment, yet my physiological risk profile, shaped by my ethnicity, places me in the same danger zone as a white patient with a BMI of 30. The ADA guidelines that flag me for annual screening and the insurance authorization forms that deny me treatment are looking at the exact same data point. The difference is that only one of them was written with an Asian body in mind.
The Disconnect: A Chronology of Mismatched Guidelines
The current crisis of access is not merely a clinical oversight; it is an administrative failure that has deepened over the last two decades.
- 2004: The World Health Organization (WHO) formally recognized that Asian populations face increased metabolic risk at lower body weights, suggesting action points for overweight and obesity at BMIs of 23 and 27.5.
- 2021-2025: A growing body of research, including the iCARDIO global obesity guidelines, confirmed that at the same BMI, individuals of Asian descent carry more visceral fat and less muscle than their European counterparts.
- June 2026: The ADA updated its Standards of Care, formally endorsing Asian-specific waist and BMI thresholds for the diagnosis of obesity.
- January–July 2026: While clinical guidelines evolved, insurance coverage retreated. Medi-Cal eliminated coverage for GLP-1s for weight loss in January, followed by MassHealth in July.
As the clinical definition of obesity moved toward inclusivity and precision, the financial gateway to treatment moved in the opposite direction, tightening just as the population that needs it most began to be recognized.
Supporting Data: Why "Standard" BMI Masks Risk
The fundamental issue is that BMI is a flawed metric when applied universally across ethnic groups. Research consistently shows that individuals of Asian descent exhibit higher rates of insulin resistance and cardiovascular disease at significantly lower BMIs than white adults.
A landmark study of nearly 1.5 million adults in England illustrated the severity of this mismatch. Researchers sought to identify the BMI at which various ethnic groups reach the same diabetes risk that white adults face at a BMI of 30. The results were startling: for South Asians, that risk threshold occurs at a BMI of 23.9; for Chinese adults, it is 26.9.
This means that a South Asian individual at a BMI of 24 is carrying the same metabolic burden as a white patient diagnosed with clinical obesity. Yet, our current healthcare system denies the former the medical interventions afforded to the latter, forcing patients to wait until their metabolic health has significantly deteriorated before they are deemed "sick enough" to qualify for help.
The Trial Inclusion Problem
Critics often argue that drug eligibility is tied to clinical trial data, which historically used a BMI of 30 as an entry criterion. However, this is a circular argument. A 2026 analysis of 352 GLP-1 trials found that BMI was the single most common barrier to entry for Asian participants. While 41.5% of non-Asian American adults met the BMI-based inclusion criteria for these trials, only 13.5% of Asian Americans and a mere 7.2% of Korean participants qualified.
By excluding non-white patients for decades, we have created a body of evidence that systematically underrepresents the very people who stand to benefit most from these therapies.
Emerging Evidence: The Efficacy of Targeted Treatment
The excuse that we "lack the data" to lower thresholds for Asian patients is becoming increasingly untenable. In 2025, the STEP 11 trial provided a glimpse into a more equitable future. By testing semaglutide 2.4 mg in South Korea and Thailand using a local obesity definition (BMI of 25+), researchers found that participants lost 16% of their body weight.
More importantly, a post-hoc analysis of 68 participants who started below the traditional American threshold of 30 saw those on semaglutide lose 17.6% of their body weight, compared to just 4.4% for the placebo group. These individuals, who would have been denied treatment in the United States, experienced profound clinical success.
Furthermore, data across eight cardiovascular outcome trials reveals that GLP-1 receptor agonists prevent major cardiac events at a higher rate in Asian participants (2.9 per 100) than in white participants (1.4 per 100). The patients with the most to gain are, ironically, the ones the current system keeps waiting.
The Regulatory Labyrinth: Why Labels Matter
Current pharmaceutical labels, including those for Wegovy and Zepbound, have technically moved away from explicit BMI numbers, opting for language like "adults with obesity, or adults with overweight plus a weight-related condition."
However, the "30" and the "27" remain embedded in the prior authorization (PA) forms used by insurers. Because the labels are intentionally broad, the burden of interpretation falls on the payer.
Global Perspectives
It is instructive to look at international systems. The United Kingdom’s National Institute for Health and Care Excellence (NICE) sets a high bar for tirzepatide access (a BMI of 35 with a comorbidity), yet they explicitly instruct prescribers to lower the threshold by 2.5 units for South Asian, Chinese, other Asian, Middle Eastern, and Black patients. A system that rations care more tightly than ours has managed to build in an ethnicity-adjusted correction. The American system, in contrast, remains stubbornly anchored to a 20th-century standard.
Implications: Re-evaluating Race-Based Medicine
There is a legitimate and necessary conversation occurring in medicine regarding the removal of race from clinical calculators. The removal of the race coefficient from the eGFR (kidney function) equation was a vital step toward racial equity, as it corrected an arbitrary multiplier that had delayed life-saving referrals for Black patients for years.
Some may argue that adjusting BMI thresholds for Asian patients is a similar form of "race-based medicine" that should be avoided. However, the logic is entirely different. The old eGFR coefficient was a correction factor that denied care; an ethnicity-adjusted BMI threshold is an evidence-based correction that widens access. It acknowledges that the physiological reality of human body composition varies across populations. Ignoring this variation is not "colorblind" medicine—it is medicine that is blind to the clinical realities of its patients.
Call to Action: The Path Forward
The path to equity does not require new legislation or a decade of new clinical trials. It requires the alignment of institutional policy with existing medical science.
- Payer Accountability: Insurance companies and pharmacy benefit managers must adopt the ethnicity-adjusted BMI bands already published by organizations like the ADA.
- Flexible Criteria: Payers should accept ethnicity-appropriate waist circumference measurements as an alternative to the rigid BMI requirement. This would provide a more accurate assessment of visceral adiposity than the scale ever could.
- Prior Authorization Reform: The "30 BMI" rule on authorization forms must be updated to reflect the 2026 clinical standards.
The current screening threshold was set low to catch metabolic disease early in Asian patients. It is a profound contradiction that the treatment threshold remains set high, preventing those same patients from receiving the very interventions that could prevent the diseases we are so eager to screen for.
It is time for payers to read the research already sitting on their desks. The science is settled; the only thing missing is the administrative will to acknowledge it.
